Abstract
Protein kinase A (PKA) hyperactivation causes hereditary endocrine neoplasias; however, its role in sporadic epithelial cancers is unknown. Here, we show that heightened PKA activity in the mammary epithelium generates tumors. Mammary-restricted biallelic ablation of Prkar1a, which encodes for the critical type-I PKA regulatory subunit, induced spontaneous breast tumors characterized by enhanced type-II PKA activity. Downstream of this, Src phosphorylation occurs at residues serine-17 and tyrosine-416 and mammary cell transformation is driven through a mechanism involving Src signaling. The phenotypic consequences of these alterations consisted of increased cell proliferation and, accordingly, expansion of both luminal and basal epithelial cell populations. In human breast cancer, low PRKAR1A/high SRC expression defines basal-like and HER2 breast tumors associated with poor clinical outcome. Together, the results of this study define a novel molecular mechanism altered in breast carcinogenesis and highlight the potential strategy of inhibiting SRC signaling in treating this cancer subtype in humans.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nadella KS, Jones GN, Trimboli A, Stratakis CA, Leone G, Kirschner LS . Targeted deletion of Prkar1a reveals a role for protein kinase A in mesenchymal-to-epithelial transition. Cancer Res 2008; 68: 2671–2677.
Tharakan R, Lepont P, Singleton D, Kumar R, Khan S . Phosphorylation of estrogen receptor alpha, serine residue 305 enhances activity. Mol Cell Endocrinol 2008; 295: 70–78.
Yin Z, Jones GN, Towns WH, Zhang X, Abel ED, Binkley PF et al. Heart-specific ablation of Prkar1a causes failure of heart development and myxomagenesis. Circulation 2008; 117: 1414–1422.
Almeida MQ, Stratakis CA . How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues? Mol Cell Endocrinol 2011; 336: 162–168.
Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van’t Veer LJ et al. PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 2011; 125: 1–12.
Moujalled D, Weston R, Anderton H, Ninnis R, Goel P, Coley A et al. Cyclic-AMP-dependent protein kinase A regulates apoptosis by stabilizing the BH3-only protein Bim. EMBO Rep 2011; 12: 77–83.
Neary CL, Nesterova M, Cho YS, Cheadle C, Becker KG, Cho-Chung YS . Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion. Oncogene 2004; 23: 8847–8856.
Miller WR . Regulatory subunits of PKA and breast cancer. Ann NY Acad Sci 2002; 968: 37–48.
Kirschner LS, Kusewitt DF, Matyakhina L, Towns WH, Carney JA, Westphal H et al. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res 2005; 65: 4506–4514.
Almeida MQ, Muchow M, Boikos S, Bauer AJ, Griffin KJ, Tsang KM et al. Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/− or Rb1+/− backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling. Hum Mol Genet 2010; 19: 1387–1398.
Bossis I, Stratakis CA . Minireview: PRKAR1A: normal and abnormal functions. Endocrinology 2004; 145: 5452–5458.
Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000; 26: 89–92.
Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis CA . Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex. Hum Mol Genet 2000; 9: 3037–3046.
Amieux PS, Mcknight GS . The essential role of RI alpha in the maintenance of regulated PKA activity. Ann NY Acad Sci 2002; 968: 75–95.
Griffin KJ, Kirschner LS, Matyakhina L, Stergiopoulos SG, Robinson-White A, Lenherr SM et al. A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1A induced lesions. J Med Genet 2004; 41: 923–931.
Wilson GR, Cramer A, Welman A, Knox F, Swindell R, Kawakatsu H et al. Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer 2006; 95: 1410–1414.
Elsberger B, Tan BA, Mitchell TJ, Brown SBF, Mallon EA, Tovey SM et al. Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients? Am J Pathol 2009; 175: 1389–1397.
Molyneux SD, Di Grappa MA, Beristain AG, Mckee TD, Wai DH, Paderova J et al. Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest 2010; 120: 3310–3325.
Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA 2010; 107: 6994–6999.
Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346–352.
Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003; 163: 2113–2126.
Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ . Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992; 89: 10578–10582.
Griffin KJ, Kirschner LS, Matyakhina L, Stergiopoulos S, Robinson-White A, Lenherr S et al. Down-regulation of regulatory subunit type 1A of protein kinase A leads to endocrine and other tumors. Cancer Res 2004; 64: 8811–8815.
Smalley MJ, Kendrick H, Sheridan JM, Regan JL, Prater MD, Lindeman GJ et al. Isolation of mouse mammary epithelial subpopulations: a comparison of leading methods. J Mammary Gland Biol Neoplasia 2012; 17: 91–97.
Fink MA, Zakhary DR, Mackey JA, Desnoyer RW, Apperson-Hansen C, Damron DS et al. AKAP-mediated targeting of protein kinase a regulates contractility in cardiac myocytes. Circulation Res 2001; 88: 291–297.
Burton KA, Johnson BD, Hausken ZE, Westenbroek RE, Idzerda RL, Scheuer T et al. Type II regulatory subunits are not required for the anchoring-dependent modulation of Ca2+ channel activity by cAMP-dependent protein kinase. Proc Natl Acad Sci USA 1997; 94: 11067–11072.
Lim CJ, Han J, Yousefi N, Ma Y, Amieux PS, Mcknight GS et al. Alpha4 integrins are type I cAMP-dependent protein kinase-anchoring proteins. Nat Cell Biol 2007; 9: 415–421.
Gold MG, Fowler DM, Means CK, Pawson CT, Stephany JJ, Langeberg LK et al. Engineering A-kinase anchoring protein (AKAP)-selective regulatory subunits of protein kinase A (PKA) through structure-based phage selection. J Biol Chem 2013; 288: 17111–17121.
Subbaramaiah K, Hudis C, Chang S-H, Hla T, Dannenberg AJ . EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem 2008; 283: 3433–3444.
Baker MA, Hetherington L, Aitken RJ . Identification of SRC as a key PKA-stimulated tyrosine kinase involved in the capacitation-associated hyperactivation of murine spermatozoa. J Cell Sci 2006; 119: 3182–3192.
Marcotte R, Smith HW, Sanguin-Gendreau V, McDonough RV, Muller WJ . Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis. Proc Natl Acad Sci USA 2012; 109: 2808–2813.
Soulard A, Cremonesi A, Moes S, Schutz F, Jenö P, Hall MN . The rapamycin-sensitive phosphoproteome reveals that TOR controls protein kinase A toward some but not all substrates. Mol Biol Cell 2010; 21: 3475–3486.
Obara Y, Labudda K, Dillon TJ, Stork PJS . PKA phosphorylation of Src mediates Rap1 activation in NGF and cAMP signaling in PC12 cells. J Cell Sci 2004; 117: 6085–6094.
Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61–70.
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353–357.
van de Vijver MJ, He YD, Van’t Veer LJ, Dai H, Hart AAM, Voskuil DW et al. A gene-expression signature as a predictor of survival in breast cancer. New Engl J Med 2002; 347: 1999–2009.
Pavel E, Nadella K, Towns WH, Kirschner LS . Mutation of Prkar1a causes osteoblast neoplasia driven by dysregulation of protein kinase A. Mol Endocrinol 2008; 22: 430–440.
Carney JA, Toorkey BC . Ductal adenoma of the breast with tubular features. A probable component of the complex of myxomas, spotty pigmentation, endocrine overactivity, and schwannomas. Am J Surg Pathol 1991; 15: 722–731.
Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 2004; 5: 597–605.
Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012; 2: 356–365.
Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 2011; 4: 329–346.
Schmitt JM, Stork PJS . PKA phosphorylation of Src mediates cAMP's inhibition of cell growth via Rap1. Mol Cell 2002; 9: 85–94.
Prat A, Parker JS, Fan C, Perou CM . PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat 2012; 135: 301–306.
Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL et al. Progesterone induces adult mammary stem cell expansion. Nature 2010; 465: 803–807.
Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS . ErbB2 but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 2001; 3: 785–792.
Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160–1167.
Tusher VG, Tibshirani R, Chu G . Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116–5121.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545–15550.
Acknowledgements
We thank Megan K Barker and Paul Waterhouse for critical reading of the manuscript. We would also like to acknowledge Shareen Ezzat for sharing the small molecule Dasatinib, Vuk Stambolic for offering insight into biochemistry experiments and the IDIBELL’s Biostatistics Unit for help in analyzing breast cancer data sets. This work was supported by a Canadian Breast Cancer Foundation (CBCF) grant to RK and the Spanish Ministry of Health grant FIS-PI12/01528 and RD12/0036/0008 to MAP. AGB holds a CBCF fellowship.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Beristain, A., Molyneux, S., Joshi, P. et al. PKA signaling drives mammary tumorigenesis through Src. Oncogene 34, 1160–1173 (2015). https://doi.org/10.1038/onc.2014.41
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2014.41